| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5824449 | Clinical Therapeutics | 2016 | 16 Pages |
Abstract
These economic analyses comparing panitumumab and cetuximab in chemorefractory wild-type KRAS (exon 2) mCRC suggest benefits in favor of panitumumab. ClinicalTrials.gov identifier: NCT01001377.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Christopher N. MS, Gregory A. PhD, Lee S. MD, FACP, Timothy J. MBBS, DHlthSc (Medicine), FRACP, Hediyyih N. MA, Guy MD, MSc, Jonas MSc, Beth PhD, Marwan G. MD,